Alprostadil ( DrugBank: Alprostadil )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 51 | 全身性強皮症 | 3 |
| 70 | 広範脊柱管狭窄症 | 1 |
51. 全身性強皮症
臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ITMCTR2100005418 | 2019-10-01 | 2021-12-17 | Observation of clinical efficacy of Ying-Pi No.1 hand mask cream in the treatment of scleroderma | Observation of clinical efficacy of Ying-Pi No.1 hand mask cream in the treatment of scleroderma | scleroderma | Test group:MTX+ Alprostadil injection + Guipiperate maleate injection + Ying-Pi No.1 hand mask cream for external application;Control group:MTX+ Alprostadil injection + Guipiperate maleate injection; | The First Affiliated Hospital of Zhejiang Chinese Medicine University | NULL | Completed | 28 | 78 | Both | Test group:30;Control group:30; | China | |
| 2 | ChiCTR2100054434 | 2019-10-01 | 2021-12-17 | Observation of clinical efficacy of Ying-Pi No.1 hand mask cream in the treatment of scleroderma | Observation of clinical efficacy of Ying-Pi No.1 hand mask cream in the treatment of scleroderma | scleroderma | Experimental group:MTX+ Alprostadil injection + Guipiperate maleate injection + Ying-Pi No.1 hand mask cream for external application;Control group:MTX+ Alprostadil injection + Guipiperate maleate injection; | The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine | NULL | Completed | 28 | 78 | Both | Experimental group:30;Control group:30; | China | |
| 3 | NCT02228850 (ClinicalTrials.gov) | November 2014 | 20/8/2014 | Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis | A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma) | Raynaud's Phenomenon Secondary to Systemic Sclerosis | Drug: Alprostadil;Other: Placebo | NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) | NULL | Completed | 18 Years | 79 Years | Both | 35 | Phase 2 | United States |
70. 広範脊柱管狭窄症
臨床試験数 : 95 / 薬物数 : 169 - (DrugBank : 61) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 90
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000005959 | 2010/11/04 | 12/07/2011 | Prospective clinical study of the therapeutic effects of prostaglandin in patients with combined lumbar spinal stenosis and arteriosclerosis obliterans showing intermittent claudication | Prospective clinical study of the therapeutic effects of prostaglandin in patients with combined lumbar spinal stenosis and arteriosclerosis obliterans showing intermittent claudication - Clinical study on therapeutic effects of prostaglandin in patients with combined lumbar spinal stenosis and arteriosclerosis obliterans | Patients with combined lumbar spinal stenosis and arteriosclerosis obliterans | Prostaglandin for injection (alprostadil) group: 60 mcg of prostaglandin for injection is intravenously administered once a week or more. This therapy is repeated 10 times or more. Ripple injection (alprostadil Injection) group: 10 mcg of ripple injection is administered intravenously once a week or more. This treatment is repeated 10 times or more. Conventional treatment group | Tokai University HospitalDepartment of Orthopaedic Surgery | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 300 | Not selected | Japan |